Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Troponin may become the "gold-standard" heart attack diagnostic tool

This article was originally published in Clinica

Executive Summary

The cardiac marker troponin could soon replace creatine kinase-MB (CK-MB) as the new "gold standard" biochemical test for diagnosing heart attack in the US. By improving a doctor's ability to evaluate patients who come to emergency rooms with chest pain, serial tests for troponin could help reduce deaths and cut down on costs associated with malpractice suits and unnecessary hospital admissions.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT083231

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel